Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!


For patients with multiagent refractory disease, CAR T-cell therapy targeting the early plasma cell antigen BCMA has shown response rates exceeding 70% and median duration of response of over 11 months.

van de Donk NWCJ et al. Lancet Haematol. [PMID: 34048683]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.